-
Press ReleaseTest New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press ReleaseNovartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
-
Press ReleaseNovartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
-
Press ReleaseNovartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press ReleaseNovartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
-
Press ReleaseNovartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
-
Press ReleaseNovartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
-
Press ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Press ReleaseNovartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH